Package Leaflet: Information for the User
Prafsia 5 mg film-coated tablets EFG
Prafsia 10 mg film-coated tablets EFG
prasugrel
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the package leaflet:
Prafsia, whose active ingredient is prasugrel, which belongs to a group of medications called antiplatelet agents. Platelets are very small cells that circulate in the blood. When a blood vessel is damaged, for example if it is cut, platelets clump together to help form a blood clot (thrombus). Therefore, platelets are essential to help stop bleeding. The formation of clots in hardened blood vessels, such as arteries, can be very dangerous as they prevent blood from passing through, causing a heart attack (myocardial infarction), stroke, or death. Clots in arteries that supply blood to the heart can also reduce blood flow, causing unstable angina (severe chest pain).
Prasugrel inhibits platelet aggregation, thereby reducing the possibility of blood clot formation.
You have been prescribed prasugrel because you have had a heart attack or unstable angina and have been treated with a procedure to open up the clogged heart arteries. You may have had one or more stents placed in the clogged or narrowed artery to restore blood flow to the heart. Prasugrel reduces the risk of future heart attacks or strokes or the risk of death due to one of these atherothrombotic events. Your doctor will also prescribe acetylsalicylic acid (e.g., aspirin), another antiplatelet agent.
Do not take Prafsia
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
You should consult your doctor or pharmacist before starting to take prasugrel if you are in any of the following situations:
You should contact your doctor immediately if you develop a disease called Thrombotic Thrombocytopenic Purpura (TTP). TTP is associated with fever and bruising under the skin that appears as red spots, with or without extreme unexplained fatigue, confusion, yellowing of the skin or eyes (jaundice) (see section 4 "Possible side effects").
Children and adolescents
Prasugrel should not be used in children or adolescents under 18 years of age.
Other medications and Prafsia
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication, including those obtained without a prescription, dietary supplements, and herbal products.
It is especially important that you inform your doctor if you are being treated with:
If taken with prasugrel, these medications may increase the risk of bleeding.
Inform your doctor if you are taking morphine or other opioids (used to treat acute pain).
Use other medications while taking prasugrel only if your doctor instructs you to do so.
Pregnancy and breastfeeding
Inform your doctor if you become pregnant or are planning to become pregnant while taking prasugrel. You should take prasugrel only after discussing the potential benefits and risks with your doctor.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and using machines
It is unlikely that prasugrel will affect your ability to drive or use machines.
Prafsia contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow the instructions for administration of this medication exactly as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The usual dose of prasugrel is 10 mg per day. Your treatment will start with a single dose of 60 mg. If your weight is less than 60 kg or you are over 75 years old, the dose is 5 mg of prasugrel per day. Your doctor will also instruct you to take acetylsalicylic acid and the exact dose you should take (usually between 75 mg and 325 mg per day).
You can take prasugrel with or without food. Take your dose every day at approximately the same time. Do not break or split the tablet.
It is important that you inform your doctor, dentist, and pharmacist that you are taking prasugrel.
If you take more Prafsia than you should
Contact your doctor or hospital directly, as you may be at risk of excessive bleeding. You should show your doctor the package of this medication.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Prafsia
If you forget to take your scheduled daily dose, take prasugrel when you remember. If you forget to take your dose for an entire day, take your usual dose of prasugrel the next day. Do not take a double dose to make up for forgotten doses.
If you interrupt treatment with Prafsia
Do not interrupt your treatment without consulting your doctor, as stopping treatment with prasugrel too soon may increase the risk of heart attack.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Contact your doctor immediately if you experience any of the following signs:
All of these can be signs of a stroke. A stroke is a rare side effect of prasugrel in patients who have never had a stroke or a transient ischemic attack (TIA).
You should also contact your doctor immediately if you notice any of the following signs:
Inform your doctor promptlyif you experience any of the following signs:
All of these can be signs of bleeding, the most common side effect with prasugrel. Although rare, severe bleeding can be life-threatening.
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the box and blister pack after "EXP". The expiration date is the last day of the month indicated.
This medication does not require any special storage temperature.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and any unused medication in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Prafsia
Prafsia 5 mg: Each tablet contains 5 mg of prasugrel (as hydrochloride).
Prafsia 10 mg: Each tablet contains 10 mg of prasugrel (as hydrochloride).
Microcrystalline cellulose (E460), mannitol (E421), sodium croscarmellose (E468), hypromellose (E464), magnesium stearate (E470b), hydroxypropylcellulose (E463), talc (E553b), titanium dioxide (E171), yellow iron oxide (E172), and red iron oxide (only 10 mg tablets) (E172).
Appearance of the product and package contents
Prafsia 5 mg: The tablets are yellow, double-arrow shaped, approximately 9.9 mm long, 4.7 mm wide, and 2.5 mm thick, engraved with "5" on one side.
Prafsia 10 mg: The tablets are dark beige, double-arrow shaped, approximately 11.1 mm long, 5.3 mm wide, and 3.8 mm thick, engraved with "10" on one side.
Prafsia 5 mg is available in DESSIFLEX-Aluminum/PE blister packs in packages of 28 and 98 tablets.
Prafsia 10 mg is available in DESSIFLEX-Aluminum/PE blister packs in packages of 28, 30, 56, and 98 tablets.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Pharmathen S.A.
Dervenakion 6 Str
Pallini 15351, Attiki
Greece
Manufacturer:
Pharmathen S.A.
Dervenakion 6 Str
Pallini 15351, Attiki
Greece
or
Pharmathen International S.A.
Industrial Park Sapes,
Rodopi Prefecture, Block No 5,
Rodopi 69300,
Greece
This medication is authorized in the Member States of the European Economic Area under the following names:
Denmark | Prafsia 5 mg film-coated tablets Prafsia 10 mg film-coated tablets |
Germany | Prafsia 5 mg film-coated tablets Prafsia 10 mg film-coated tablets |
Greece | Prafsia 5 mg film-coated tablets Prafsia 10 mg film-coated tablets |
Spain | Prafsia 5 mg film-coated tablets EFG Prafsia 10 mg film-coated tablets EFG |
France | PRAFSIA 5 mg, film-coated tablet PRAFSIA 10 mg, film-coated tablet |
Italy | Prafsia 5 mg film-coated tablets Prafsia 10 mg film-coated tablets |
Date of last revision of this package leaflet:July 2024.
Detailed information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.